141 related articles for article (PubMed ID: 36573450)
1. Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers.
Younis IR; Kirby BJ; Billin AN; Xiao D; Song Q; Watkins TR; Othman AA
Clin Transl Sci; 2023 Mar; 16(3):536-547. PubMed ID: 36573450
[TBL] [Abstract][Full Text] [Related]
2. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Patel K; Harrison SA; Elkhashab M; Trotter JF; Herring R; Rojter SE; Kayali Z; Wong VW; Greenbloom S; Jayakumar S; Shiffman ML; Freilich B; Lawitz EJ; Gane EJ; Harting E; Xu J; Billin AN; Chung C; Djedjos CS; Subramanian GM; Myers RP; Middleton MS; Rinella M; Noureddin M
Hepatology; 2020 Jul; 72(1):58-71. PubMed ID: 32115759
[TBL] [Abstract][Full Text] [Related]
3. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study.
Xu J; Zhang H; Chen H; Zhu X; Jia H; Xu Z; Huo D; Zhang H; Li C; Ding Y
Ann Med; 2023; 55(2):2264850. PubMed ID: 38071661
[No Abstract] [Full Text] [Related]
5. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
[TBL] [Abstract][Full Text] [Related]
7. Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
Younis IR; Hsueh CH; Nelson C; Billin AN; Yue MS; Xiao D; Watkins TR; Othman AA
J Clin Pharmacol; 2023 Sep; 63(9):1017-1025. PubMed ID: 37128693
[TBL] [Abstract][Full Text] [Related]
8. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
9. Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers.
Wang Y; Crittenden DB; Eng C; Zhang Q; Guo P; Chung D; Fenaux M; Klucher K; Jones C; Jin F; Quirk E; Charlton MR
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1198-1208. PubMed ID: 34302449
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
Weber EJ; Younis IR; Wang L; Xiao D; Barchuk WT; Othman AA
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):677-687. PubMed ID: 38346861
[TBL] [Abstract][Full Text] [Related]
11. Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor.
Jiang L; Liu X; Wei H; Dai S; Qu L; Chen X; Guo M; Chen Y
Biochem Biophys Res Commun; 2022 Mar; 595():1-6. PubMed ID: 35091108
[TBL] [Abstract][Full Text] [Related]
12. Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
Weber E; Younis IR; Nelson C; Ding D; Qin A; Xiao D; Watkins TR; Othman AA
J Clin Pharmacol; 2023 May; 63(5):560-568. PubMed ID: 36700458
[TBL] [Abstract][Full Text] [Related]
13. Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist.
He H; Wu JJ
Drugs R D; 2023 Dec; 23(4):453-464. PubMed ID: 37919483
[TBL] [Abstract][Full Text] [Related]
14. PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
Trauner M; Chung C; Sterling K; Liu X; Lu X; Xu J; Tempany-Afdhal C; Goodman ZD; Färkkilä M; Tanaka A; Trivedi P; Kowdley KV; Bowlus CL; Levy C; Myers RP
BMC Gastroenterol; 2023 Mar; 23(1):75. PubMed ID: 36922785
[TBL] [Abstract][Full Text] [Related]
15. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
Palmer M; Jennings L; Silberg DG; Bliss C; Martin P
BMC Pharmacol Toxicol; 2018 Mar; 19(1):10. PubMed ID: 29548345
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers.
Badman MK; Chen J; Desai S; Vaidya S; Neelakantham S; Zhang J; Gan L; Danis K; Laffitte B; Klickstein LB
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):395-410. PubMed ID: 31823525
[TBL] [Abstract][Full Text] [Related]
17. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Xu J; Wang Y; Khoshdeli M; Peach M; Chuang JC; Lin J; Tsai WW; Mahadevan S; Minto W; Diehl L; Gupta R; Trauner M; Patel K; Noureddin M; Kowdley KV; Gulamhusein A; Bowlus CL; Huss RS; Myers RP; Chung C; Billin AN
Hepatology; 2023 Jan; 77(1):20-32. PubMed ID: 35686937
[TBL] [Abstract][Full Text] [Related]
18. Development of Cilofexor, an intestinally-biased Farnesoid X Receptor agonist, for the treatment of fatty liver disease.
Hollenback D; Hambruch E; Fink G; Birkel M; Schulz A; Hornberger M; Liu K; Staiger KM; Krol HD; Deuschle U; Steeneck C; Kinzel O; Liles JT; Budas G; Watkins WJ; Kremoser C
J Pharmacol Exp Ther; 2024 Feb; ():. PubMed ID: 38409114
[TBL] [Abstract][Full Text] [Related]
19. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
